FTC insists generics ANI and Novitium divest IP before merger

11-11-2021

Muireann Bolger

FTC insists generics ANI and Novitium divest IP before merger

jer123 / Shutterstock.com

The Federal Trade Commission (FTC) has stipulated that generic drug marketers ANI Pharmaceuticals, and Novitium Pharma must divest IP rights to Prasco ahead of their $210 million merger. 


generic, Novitium, SMX-TMP, dexamethasone, Prasco, Commission, pharmaceutical, generics, FTC, Ani, Novitum, Prasco, Merger, generics

LSIPR